The rationale is that uPAR activity fosters a myeloid-driven, immunosuppressive tumor microenvironment that limits cytotoxic T-cell access; inhibiting uPAR should relieve this brake and improve checkpoint efficacy [168]. This evidence concerns the gene PLAUR and neoplasm.